IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA
Identifieur interne : 000610 ( Pmc/Checkpoint ); précédent : 000609; suivant : 000611IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA
Auteurs : Johan Nilvebrant [Suède] ; D Cameron Dunlop [États-Unis] ; Aroop Sircar [États-Unis] ; Thierry Wurch [France] ; Emilia Falkowska [États-Unis] ; Janice M. Reichert [États-Unis] ; Gustavo Helguera [Argentine] ; Emily C. Piccione [États-Unis] ; Simon Brack [Suisse] ; Sven Berger [France]Source :
- mAbs [ 1942-0862 ] ; 2012.
Abstract
The 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5–8, 2011 in San Diego, CA. The meeting drew ∼800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics Conference comprised five sessions: (1) Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.
Url:
DOI: 10.4161/mabs.4.2.19495
PubMed: 22453091
PubMed Central: 3361653
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:3361653Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA</title><author><name sortKey="Nilvebrant, Johan" sort="Nilvebrant, Johan" uniqKey="Nilvebrant J" first="Johan" last="Nilvebrant">Johan Nilvebrant</name><affiliation wicri:level="1"><nlm:aff id="A1">School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Dunlop, D Cameron" sort="Dunlop, D Cameron" uniqKey="Dunlop D" first="D Cameron" last="Dunlop">D Cameron Dunlop</name><affiliation wicri:level="2"><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Scripps Research Institute; La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Sircar, Aroop" sort="Sircar, Aroop" uniqKey="Sircar A" first="Aroop" last="Sircar">Aroop Sircar</name><affiliation wicri:level="2"><nlm:aff id="A3">EMD Serono Research Institute; Billlerica, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>EMD Serono Research Institute; Billlerica</wicri:cityArea></affiliation></author><author><name sortKey="Wurch, Thierry" sort="Wurch, Thierry" uniqKey="Wurch T" first="Thierry" last="Wurch">Thierry Wurch</name><affiliation wicri:level="1"><nlm:aff id="A4">Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine</wicri:regionArea></affiliation></author><author><name sortKey="Falkowska, Emilia" sort="Falkowska, Emilia" uniqKey="Falkowska E" first="Emilia" last="Falkowska">Emilia Falkowska</name><affiliation wicri:level="2"><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Scripps Research Institute; La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M" last="Reichert">Janice M. Reichert</name><affiliation wicri:level="2"><nlm:aff id="A5">Landes Bioscience; Austin, TX USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Landes Bioscience; Austin</wicri:cityArea></affiliation></author><author><name sortKey="Helguera, Gustavo" sort="Helguera, Gustavo" uniqKey="Helguera G" first="Gustavo" last="Helguera">Gustavo Helguera</name><affiliation wicri:level="1"><nlm:aff id="A6">Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires, Argentina</nlm:aff><country xml:lang="fr">Argentine</country><wicri:regionArea>Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires</wicri:regionArea></affiliation></author><author><name sortKey="Piccione, Emily C" sort="Piccione, Emily C" uniqKey="Piccione E" first="Emily C" last="Piccione">Emily C. Piccione</name><affiliation wicri:level="2"><nlm:aff id="A7">Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Stanford Cancer Institute; Stanford University School of Medicine; Stanford</wicri:cityArea></affiliation></author><author><name sortKey="Brack, Simon" sort="Brack, Simon" uniqKey="Brack S" first="Simon" last="Brack">Simon Brack</name><affiliation wicri:level="1"><nlm:aff id="A8">Covagen AG; Zürich Schlieren, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Covagen AG; Zürich Schlieren</wicri:regionArea></affiliation></author><author><name sortKey="Berger, Sven" sort="Berger, Sven" uniqKey="Berger S" first="Sven" last="Berger">Sven Berger</name><affiliation wicri:level="1"><nlm:aff id="A9">Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22453091</idno><idno type="pmc">3361653</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361653</idno><idno type="RBID">PMC:3361653</idno><idno type="doi">10.4161/mabs.4.2.19495</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000336</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000336</idno><idno type="wicri:Area/Pmc/Curation">000334</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000334</idno><idno type="wicri:Area/Pmc/Checkpoint">000610</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000610</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA</title><author><name sortKey="Nilvebrant, Johan" sort="Nilvebrant, Johan" uniqKey="Nilvebrant J" first="Johan" last="Nilvebrant">Johan Nilvebrant</name><affiliation wicri:level="1"><nlm:aff id="A1">School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Dunlop, D Cameron" sort="Dunlop, D Cameron" uniqKey="Dunlop D" first="D Cameron" last="Dunlop">D Cameron Dunlop</name><affiliation wicri:level="2"><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Scripps Research Institute; La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Sircar, Aroop" sort="Sircar, Aroop" uniqKey="Sircar A" first="Aroop" last="Sircar">Aroop Sircar</name><affiliation wicri:level="2"><nlm:aff id="A3">EMD Serono Research Institute; Billlerica, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>EMD Serono Research Institute; Billlerica</wicri:cityArea></affiliation></author><author><name sortKey="Wurch, Thierry" sort="Wurch, Thierry" uniqKey="Wurch T" first="Thierry" last="Wurch">Thierry Wurch</name><affiliation wicri:level="1"><nlm:aff id="A4">Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine</wicri:regionArea></affiliation></author><author><name sortKey="Falkowska, Emilia" sort="Falkowska, Emilia" uniqKey="Falkowska E" first="Emilia" last="Falkowska">Emilia Falkowska</name><affiliation wicri:level="2"><nlm:aff id="A2">The Scripps Research Institute; La Jolla, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Scripps Research Institute; La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M" last="Reichert">Janice M. Reichert</name><affiliation wicri:level="2"><nlm:aff id="A5">Landes Bioscience; Austin, TX USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Landes Bioscience; Austin</wicri:cityArea></affiliation></author><author><name sortKey="Helguera, Gustavo" sort="Helguera, Gustavo" uniqKey="Helguera G" first="Gustavo" last="Helguera">Gustavo Helguera</name><affiliation wicri:level="1"><nlm:aff id="A6">Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires, Argentina</nlm:aff><country xml:lang="fr">Argentine</country><wicri:regionArea>Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires</wicri:regionArea></affiliation></author><author><name sortKey="Piccione, Emily C" sort="Piccione, Emily C" uniqKey="Piccione E" first="Emily C" last="Piccione">Emily C. Piccione</name><affiliation wicri:level="2"><nlm:aff id="A7">Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Stanford Cancer Institute; Stanford University School of Medicine; Stanford</wicri:cityArea></affiliation></author><author><name sortKey="Brack, Simon" sort="Brack, Simon" uniqKey="Brack S" first="Simon" last="Brack">Simon Brack</name><affiliation wicri:level="1"><nlm:aff id="A8">Covagen AG; Zürich Schlieren, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Covagen AG; Zürich Schlieren</wicri:regionArea></affiliation></author><author><name sortKey="Berger, Sven" sort="Berger, Sven" uniqKey="Berger S" first="Sven" last="Berger">Sven Berger</name><affiliation wicri:level="1"><nlm:aff id="A9">Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois</wicri:regionArea></affiliation></author></analytic><series><title level="j">mAbs</title><idno type="ISSN">1942-0862</idno><idno type="eISSN">1942-0870</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The 22<sup>nd</sup> Annual Antibody Engineering and 9<sup>th</sup> Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5–8, 2011 in San Diego, CA. The meeting drew ∼800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics Conference comprised five sessions: (1) Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.</p></div></front></TEI><pmc article-type="brief-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">MAbs</journal-id><journal-id journal-id-type="iso-abbrev">MAbs</journal-id><journal-id journal-id-type="publisher-id">mAbs</journal-id><journal-title-group><journal-title>mAbs</journal-title></journal-title-group><issn pub-type="ppub">1942-0862</issn><issn pub-type="epub">1942-0870</issn><publisher><publisher-name>Landes Bioscience</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22453091</article-id><article-id pub-id-type="pmc">3361653</article-id><article-id pub-id-type="publisher-id">1942-0862-4-2-3</article-id><article-id pub-id-type="doi">10.4161/mabs.4.2.19495</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Report</subject></subj-group></article-categories><title-group><article-title>IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nilvebrant</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dunlop</surname><given-names>D Cameron</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sircar</surname><given-names>Aroop</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wurch</surname><given-names>Thierry</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Falkowska</surname><given-names>Emilia</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Reichert</surname><given-names>Janice M</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Helguera</surname><given-names>Gustavo</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Piccione</surname><given-names>Emily C</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Brack</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Berger</surname><given-names>Sven</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib></contrib-group><aff id="A1"><label>1</label>School of Biotechnology; Department of Proteomics; Royal Institute of Technology (KTH); AlbaNova University Center; Stockholm, Sweden</aff><aff id="A2"><label>2</label>The Scripps Research Institute; La Jolla, CA USA</aff><aff id="A3"><label>3</label>EMD Serono Research Institute; Billlerica, MA USA</aff><aff id="A4"><label>4</label>Oncology Research Division; Institut de Recherche SERVIER; Croissy sur Seine, France</aff><aff id="A5"><label>5</label>Landes Bioscience; Austin, TX USA</aff><aff id="A6"><label>6</label>Farmacotecnia I; Facultad de Farmacia y Bioquímica; University of Buenos Aires; Ciudad Autónoma de Buenos Aires, Argentina</aff><aff id="A7"><label>7</label>Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA</aff><aff id="A8"><label>8</label>Covagen AG; Zürich Schlieren, Switzerland</aff><aff id="A9"><label>9</label>Institut de Recherche Pierre Fabre; Centre d'Immunologie Pierre Fabre; St. Julien en Genevois, France</aff><author-notes><corresp>Correspondence to: Janice M. Reichert; Email: <email>janice.reichert@landesbioscience.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2012</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2012</year></pub-date><volume>4</volume><issue>2</issue><fpage>153</fpage><lpage>181</lpage><history><date date-type="received"><day>26</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2012 Landes Bioscience</copyright-statement><copyright-year>2012</copyright-year></permissions><abstract><p>The 22<sup>nd</sup> Annual Antibody Engineering and 9<sup>th</sup> Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5–8, 2011 in San Diego, CA. The meeting drew ∼800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics Conference comprised five sessions: (1) Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.</p></abstract><kwd-group><title>Key words</title><kwd>antibody engineering</kwd><kwd>antibody therapeutics</kwd><kwd>antibody-drug conjugates</kwd><kwd>bispecific antibodies</kwd><kwd>computational design</kwd><kwd>antibody-antigen structure</kwd><kwd>vaccine design</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>Argentine</li><li>France</li><li>Suisse</li><li>Suède</li><li>États-Unis</li></country><region><li>Californie</li><li>Massachusetts</li><li>Texas</li></region></list><tree><country name="Suède"><noRegion><name sortKey="Nilvebrant, Johan" sort="Nilvebrant, Johan" uniqKey="Nilvebrant J" first="Johan" last="Nilvebrant">Johan Nilvebrant</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Dunlop, D Cameron" sort="Dunlop, D Cameron" uniqKey="Dunlop D" first="D Cameron" last="Dunlop">D Cameron Dunlop</name></region><name sortKey="Falkowska, Emilia" sort="Falkowska, Emilia" uniqKey="Falkowska E" first="Emilia" last="Falkowska">Emilia Falkowska</name><name sortKey="Piccione, Emily C" sort="Piccione, Emily C" uniqKey="Piccione E" first="Emily C" last="Piccione">Emily C. Piccione</name><name sortKey="Reichert, Janice M" sort="Reichert, Janice M" uniqKey="Reichert J" first="Janice M" last="Reichert">Janice M. Reichert</name><name sortKey="Sircar, Aroop" sort="Sircar, Aroop" uniqKey="Sircar A" first="Aroop" last="Sircar">Aroop Sircar</name></country><country name="France"><noRegion><name sortKey="Wurch, Thierry" sort="Wurch, Thierry" uniqKey="Wurch T" first="Thierry" last="Wurch">Thierry Wurch</name></noRegion><name sortKey="Berger, Sven" sort="Berger, Sven" uniqKey="Berger S" first="Sven" last="Berger">Sven Berger</name></country><country name="Argentine"><noRegion><name sortKey="Helguera, Gustavo" sort="Helguera, Gustavo" uniqKey="Helguera G" first="Gustavo" last="Helguera">Gustavo Helguera</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Brack, Simon" sort="Brack, Simon" uniqKey="Brack S" first="Simon" last="Brack">Simon Brack</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000610 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000610 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:3361653
|texte= IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:22453091" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |